MTOR

mTOR (mechanistic Target of Rapamycin) is the nutrient-sensing master switch that determines whether a cell should grow and divide or conserve and repair. It exists in two distinct complexes: mTORC1, which is acutely sensitive to rapamycin and nutrients, and mTORC2, which responds primarily to growth factors and regulates the cytoskeleton and survival.

In the presence of amino acids, insulin, and energy (ATP), mTORC1 is recruited to the lysosomal surface where it is activated by Rheb. Once active, it phosphorylates S6K1 and 4E-BP1 to drive protein synthesis while simultaneously inhibiting ULK1 to suppress autophagy. This anabolic state is essential for growth but, when chronically active, accelerates aging and drives age-related diseases.

Inhibiting mTOR — whether through caloric restriction, fasting, exercise, or pharmacology (rapamycin) — is the most robustly validated intervention for extending lifespan across model organisms. By shifting the cellular state from growth to maintenance, mTOR inhibition promotes cellular "cleanup" via autophagy and improves proteostasis, making it the central hub of longevity biology.

Activation Mechanics: Lysosomal Recruitment and Dual Inputs

mTORC1 activation is spatially gated at the lysosomal surface through a two-signal coincidence-detection mechanism. The first signal comes from amino acids — particularly leucine (sensed by Sestrin2) and arginine (sensed by CASTOR1). These sensors converge on the GATOR1 and GATOR2 super-complexes, controlling whether Rag GTPases (RagA/B in GTP form; RagC/D in GDP form) reach their active configuration.

Active Rag heterodimers, anchored to the lysosomal membrane by the Ragulator scaffold (LAMTOR1–5), physically recruit mTORC1 by binding RPTOR/Raptor. This lysosomal translocation is necessary but insufficient: mTOR must also encounter Rheb-GTP.

The second signal, from growth factors via PI3K–AKT, inactivates the TSC1/TSC2 GAP complex, allowing Rheb to remain GTP-loaded on the lysosomal membrane. Only when both conditions are met — Rag-mediated docking and Rheb-GTP activation — does mTORC1 achieve full catalytic output. This coincidence-detection logic ensures mTOR is active only when both building blocks and anabolic demand are simultaneously present.

Substrate Specificity: mTORC1 vs mTORC2

Despite sharing the same mTOR catalytic subunit, mTORC1 and mTORC2 phosphorylate almost entirely non-overlapping substrates by virtue of their distinct scaffold proteins. mTORC1, assembled around RPTOR/Raptor, engages substrates containing a TOS (TOR signaling) motif via Raptor’s HEAT repeats. This restricts its primary substrates to S6K1, 4E-BP1, ULK1, TFEB, Lipin1, and GRB10 — all players in the acute anabolic or anti-catabolic response.

mTORC2, assembled around RICTOR and mSin1, lacks Raptor entirely and phosphorylates the hydrophobic motifs of AGC-family kinases: AKT at Ser473, SGK1 at Ser422, and PKCα at Ser657. This wires mTORC2 into cell survival, cytoskeletal reorganization, and ion transport rather than translation control.

Crucially, mTORC1 is acutely rapamycin-sensitive (FKBP12–rapamycin binds the FRB domain), whereas mTORC2 is rapamycin-insensitive under acute dosing, though prolonged treatment can disrupt mTORC2 assembly in some cell types by sequestering the free mTOR pool.

Feedback Loops That Shape Chronic vs Transient Output

The PI3K -> AKT -> mTOR axis is widely depicted as a linear chain, but its behavior in chronic nutrient excess is dominated by feedback architecture. The most consequential loop is the S6K1 -> IRS1 negative feedback: when mTORC1 is persistently active, S6K1 phosphorylates IRS1 on multiple inhibitory serine residues, targeting it for degradation and uncoupling it from the insulin receptor.

This means that in the chronically overfed state, downstream mTORC1 remains active even as receptor-proximal insulin signaling becomes blunted — generating the “dissociated insulin resistance” where the pathway selectively rewires rather than shuts down. This is why obesity creates insulin resistance but not mTOR resistance.

mTORC2 adds complexity: as both upstream activator of AKT (Ser473) and a regulator within broader nutrient/cytoskeletal signaling, it helps determine signal duration and cell-type-specific outputs. Chronic rapamycin disrupts mTORC2 assembly in some tissues, potentially worsening insulin resistance — one argument for intermittent dosing strategies.

Rapamycin: Mechanism, Dosing, and the Intermittent Hypothesis

Rapamycin (sirolimus) inhibits mTOR through an allosteric mechanism distinct from ATP-competitive kinase inhibitors. It binds intracellularly to the immunophilin FKBP12, and the resulting complex docks on the FRB domain of mTOR, sterically occluding substrate recruitment. This mechanism partially inhibits mTORC1 — it fully dephosphorylates S6K1 but only partially dephosphorylates 4E-BP1, particularly its Thr37/46 priming sites.

The intermittent rapamycin hypothesis emerges from two observations: (1) continuous high-dose rapamycin disrupts mTORC2 assembly over time, impairing AKT Ser473 phosphorylation and worsening glucose tolerance; (2) mTORC1 substrate phosphorylation recovers incompletely between weekly doses, providing durable inhibition without sustained drug levels.

Multiple mouse studies using once-weekly rapamycin extend lifespan with improved side-effect profiles versus daily dosing. In humans, 2–6 mg weekly is under investigation. The mechanistic rationale — capture mTORC1 inhibition, spare mTORC2 — remains the leading hypothesis but has not been definitively proven in human tissue.